Petros Pharmaceuticals Inc. (PTPI): Price and Financial Metrics

Petros Pharmaceuticals Inc. (PTPI): $1.46

0.01 (+0.34%)

POWR Rating

Component Grades













PTPI Stock Summary

  • With a market capitalization of $2,899,123, PETROS PHARMACEUTICALS INC has a greater market value than only 0.64% of US stocks.
  • The volatility of PETROS PHARMACEUTICALS INC's share price is greater than that of 96.85% US stocks with at least 200 days of trading history.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for PTPI comes in at -778.78% -- higher than that of only 0.99% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to PETROS PHARMACEUTICALS INC, a group of peers worth examining would be BXRX, AYTU, PRLB, TKNO, and MRAI.
  • To check out PETROS PHARMACEUTICALS INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001815903.

PTPI Valuation Summary

  • In comparison to the median Healthcare stock, PTPI's price/earnings ratio is 100.43% lower, now standing at -0.1.
  • PTPI's price/sales ratio has moved down 1.8 over the prior 28 months.

Below are key valuation metrics over time for PTPI.

Stock Date P/S P/B P/E EV/EBIT
PTPI 2023-03-24 0.7 0.1 -0.1 -0.1
PTPI 2023-03-23 0.7 0.2 -0.1 -0.1
PTPI 2023-03-22 0.7 0.1 -0.1 -0.1
PTPI 2023-03-21 0.7 0.1 -0.1 -0.1
PTPI 2023-03-20 0.7 0.2 -0.1 -0.1
PTPI 2023-03-17 0.7 0.2 -0.1 -0.1

PTPI Stock Price Chart Interactive Chart >

Price chart for PTPI

PTPI Price/Volume Stats

Current price $1.46 52-week high $28.80
Prev. close $1.45 52-week low $1.32
Day low $1.38 Volume 6,100
Day high $1.50 Avg. volume 16,810
50-day MA $2.21 Dividend yield N/A
200-day MA $4.79 Market Cap 3.01M

Petros Pharmaceuticals Inc. (PTPI) Company Bio

Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, a FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.

PTPI Latest News Stream

Event/Time News Detail
Loading, please wait...

PTPI Latest Social Stream

Loading social stream, please wait...

View Full PTPI Social Stream

Latest PTPI News From Around the Web

Below are the latest news stories about PETROS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PTPI as an investment opportunity.

Petros Pharmaceuticals Announces Reverse Stock Split

Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (Nasdaq:PTPI), a leading provider of therapeutics for men's health, today announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 10 pre-split shares. The reverse stock split will become effective at 4:05 p.m. on Wednesday, November 30, 2022.

Yahoo | November 30, 2022

Petros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Update

Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announced financial results for the third quarter ended September 30, 2022.

Yahoo | November 15, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Pre-market stock movers continue to be a major topic as we dive into the latest news investors need to know about on Friday!

William White on InvestorPlace | October 28, 2022

New FDA-Approved Labeling for Petros Pharmaceuticals’ STENDRA (avanafil) Now Includes Efficacy Data Regarding Use in Men Who Have Undergone Radical Prostatectomy

Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a leading provider of therapeutics for men's health, today announces the expansion of the FDA labeling for its oral erectile dysfunction (ED) drug, STENDRA® (avanafil), marketed by its subsidiary, Metuchen Pharmaceuticals.

Yahoo | October 25, 2022

Petros Pharmaceuticals to Participate in Two October 2022 Conferences

/ Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Officer Fady Boctor will participate in two October 2022 conferences.

Yahoo | October 21, 2022

Read More 'PTPI' Stories Here

PTPI Price Returns

1-mo -28.78%
3-mo -39.54%
6-mo -71.37%
1-year -89.57%
3-year N/A
5-year N/A
YTD -37.34%
2022 -93.00%
2021 -24.32%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8473 seconds.